Advertisement

Topics

Understanding the abbreviated licensure pathway: Q&A with FDA's Leah Christl

00:00 EDT 29 Jun 2017 | Healio

To clarify some of the procedural details and concerns surrounding the abbreviated licensure pathway for biosimilars, Healio spoke with Leah Christl, PhD, associate director for therapeutic biologics at FDA.

Original Article: Understanding the abbreviated licensure pathway: Q&A with FDA's Leah Christl

NEXT ARTICLE

More From BioPortfolio on "Understanding the abbreviated licensure pathway: Q&A with FDA's Leah Christl"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...